Document:

EX-10.13

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [****], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 Exhibit 10.13 

PATENT LICENSE AGREEMENT 

THIS PATENT LICENSE AGREEMENT (this “Agreement”), dated as of this 15th day of July, 2020 (the “Effective
Date”), by and between Eiken Chemical Co., Ltd., a corporation organized and existing under the laws of Japan with its principal place of business at 19-9, Taito
4-chome, Taito-ku, Tokyo, Japan (“Eiken”) and Lucira Health, Inc., a corporation organized and existing under the laws of Delaware with its
principal place of business at 1412 62nd Street, Emeryville, CA 94608 U.S.A. (“Lucira”). 
 RECITALS

 Eiken has developed proprietary technology relating to the nucleic acid amplification referred to as “Loop-mediated
Isothermal Amplification” (the “LAMP”) and owns and has rights under certain patents and patent applications in respect of the LAMP in various countries of the world. 

Lucira wishes to obtain licenses under the LAMP Patents (as defined later) to develop, manufacture, use and sell certain products in the Field
(as defined later). 
 Eiken is willing to grant such license under the LAMP Patents under the terms and conditions hereinafter contained.

 NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 ARTICLE I 

DEFINITIONS; INTERPRETATION 

Section 1.01. As used in this Agreement, except as otherwise expressly provided herein or unless the
context herein otherwise requires, the following terms shall have the respective meanings indicated below: 
 “Additional
Target” has the meaning set forth in Section 2.03. 
 “Affiliate” means any corporation, company,
partnership or entity that directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with, either Party. For purposes of this definition, control means the direct or indirect legal or beneficial
ownership of greater than fifty percent (50%) of the outstanding shares of stock entitled to vote for the election of directors or persons performing similar functions, or in the case of entity not having voting stock, equivalent ownership or
interest of greater than fifty percent (50%) of its outstanding shares, or of its net asset or net profit; provided that such corporation, company, partnership or entity shall be deemed to be an Affiliate for purposes of this Agreement only
so long as such Party maintains such ownership or control. The terms “control” or “controlled by” shall have correlative meanings. 

  
 1 

 “Agreement” has the meaning set forth in the preamble hereof and
includes all Schedules, which may be amended, modified, revised or supplemented from time to time upon agreement of the Parties. 

“Arm’s Length Customer” means any customer, purchaser or third
party having no financial interest or capital investments in Lucira or any of its Affiliates sublicensed hereunder in the first bona-fide arm’s length sale from Lucira or such Affiliate of the Licensed Products to such customer, purchaser or
third party, and includes any distributor, wholesaler or other bona-fide third party purchaser of Licensed Products from Lucira or its Affiliates sublicensed hereunder. For the avoidance of doubt, the transfer or sales from Lucira to an Affiliate of
Lucira or from any of Lucira’s Affiliates to another Affiliate of Lucira shall not be considered to be sales to Arm’s Length Customer. 

“Change of Control” means at any time prior to consummation of the initial public offering of Lucira stock any
transaction or event (or series of transactions or events), whether by an acquisition of securities, merger, consolidation, proxy contest or other transaction or event (or series of transactions or events), that results in Lucira being controlled,
directly or indirectly, by a third person (whether alone or with others) that did not control Lucira before such transaction or event (or series of transactions or events), whether or not Lucira survives such transaction or event (or series of
transactions or events). For purposes of this definition, “control” means possession of, or the power or right to acquire possession of, directly or indirectly, the power to direct or cause the direction of the management, business affairs
or policies of Lucira (whether through ownership of securities, partnership or other ownership interests, by contract or otherwise). 

“Effective Date” has the meaning set forth in the preamble hereof. 

“Field” means [****]. 

“Initial Target” means severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 (formerly 2019-nCoV), which causes coronavirus disease (COVID-19). 

“Interest Rate” means, with respect to any amount, the interest rate of [****] percent ([****]) per annum subject to
the maximum statutory rate of default interest permissible under applicable law. 
 “LAMP” has the meaning set forth
in the first Recital. 
 “LAMP Patents” means the patents set forth in Schedule I and any division, amendment,
inter partes review, reexamination, renewal, re-issue and extension of any of the foregoing patents. 

“License Fees” has the meaning set forth in Section 3.01. 

“Licensed Product(s)” means any reagent, product, kit, device, equipment, instrument and/or system for nucleic
acid-based in-vitro diagnostic tests for (i) the detection of a target or targets contained in the Initial Target prior to the exercise of the option set 

  
 2 

 
forth in Section 2.02 and (ii) the detection of an Additional Target or Additional Targets after the exercise of the option set forth in Section 2.04, the manufacturing, selling,
offering for sale, importing or otherwise disposing of which would constitute, but for the license herein, an infringement of any of the LAMP Patents. 

“Licensed Territory” means (i) only the United States of America under the licenses granted by Sections
2.01 and 2.03, and (ii) anywhere in the world under the licenses granted by Sections 2.02 and 2.04. 
 “Lucira
Technology” means the technology claimed in the US patents and US patent applications listed in Schedule III. 

“Net Sales” means the gross invoice price actually invoiced (or if not invoiced, the gross price actually charged) for
a Licensed Product sold by Lucira or any of its Affiliates to any Arm’s Length Customer (excluding a Licensed Product transferred, sold or otherwise disposed of by Lucira to any of its Affiliates or by any of its Affiliates to another Affiliate
thereof) minus 
  

	 	(i)	 sales tax, GST or PST, tariffs, duties, VAT, use tax, excise tax, and other governmental charges levied with
respect to the sale, transportation, delivery, use, exportation, or importation of a Licensed Product (which does not include income taxes), where such tax or other governmental charge is itemized in the invoice and actually included in such gross
invoice price or gross charge; and 

  

	 	(ii)	 [****]. 

provided, however, that (a) when a Licensed Product is used or otherwise disposed of without payment, the Net Sale of such Licensed Product shall
be [****]. 
 “Party” means either Eiken or Lucira, and “Parties” means collectively Eiken
and Lucira. 
 “Running Royalties” has the meaning set forth in Section 3.02. 

“Treaty” has the meaning set forth in Section 4.05. 

“USGAAP” means generally accepted accounting principles in the United States of America in effect at the time of
keeping the books of accounts set forth in Section 4.08. 
 Section 1.02. Interpretation 

(a) The phrase “to use the Licensed Products” means to incorporate the Licensed Products into any other products. 

(b) The term “including” means “including without limitation”. 

(c) The words “herein”, “hereof”, “hereto” and “hereunder” refer to this Agreement as a whole, and not
to any particular Article, Section or Subsection in this Agreement. 
 (d) Headings and Recitals are inserted for convenience only and do
not affect the construction hereof, words denoting the singular include the plural and vice versa, and words denoting one gender include each gender and all genders. 

  
 3 

 (e) Where an expression is defined, another part of speech or grammatical form of that
expression has a corresponding meaning. 
 (f) Unless the context otherwise requires, references herein to: 

(i) a person include references to a natural person, firm, partnership, joint venture, company, corporation, association, organization, trust,
enterprise, government or department or agency of any government (in each case whether or not having a separate legal personality); 
 (ii) a
month, quarter and year are references to a month, quarter and year of the Gregorian Calendar; 
 (iii) Recitals, Articles, Sections,
Subsection or Schedule refer to the appropriate recitals, articles, sections, subsections or schedules hereof; 
 (iv) a document, instrument
and agreement are references to such document, instrument and agreement (including schedules thereto and, where applicable, any of its provisions) as amended, modified, varied, supplemented, novated or replaced and in effect at the time any such
reference is operative; 
 (v) a Party include its permitted successors and assigns; 

(vi) a statute or law are construed as references to such statute or law as modified, amended, consolidated, extended or re-enacted and in effect at the time any such reference is operative, and include any administrative guidances, orders, regulations, instruments or other subordinate legislation made under the relevant statute or
law; and 
 (vii) an authority, association or body whether statutory or otherwise are, if and when any such authority, association or body
ceases to exist or is reconstituted, renamed or replaced or the powers or functions thereof are transferred to any other authority, association or body, references respectively to the authority, association or body established or constituted in lieu
thereof or as nearly as may be succeeding to the powers or functions thereof. 
 ARTICLE II 

GRANT OF LICENSE 

Section 2.01. Subject to the terms and conditions set forth herein, during the effective term hereof, Eiken
hereby grants to Lucira, and Lucira hereby accepts, non-transferable, non-assignable (except in connection with a permitted assignment pursuant to Section 9.01), non-exclusive license, with the right to sublicense in accordance with Section 2.05, under the LAMP Patents to develop, and make Licensed Products for the Initial Target in the Field in the United States of
America, and use, sell, offer for sale or otherwise dispose of the Licensed Products so made under Lucira’s own labels in the Field in the United States of America (the Licensed Territory). 

Section 2.02. Subject to the terms and conditions set forth herein,
Eiken hereby grants to Lucira, and Lucira hereby accepts, during the effective term hereof, an option to expand the licensed territory from the United States of America to anywhere in the world under the license set forth in Section 2.01.
Lucira may exercise the option at any time upon the payment of the fee set forth in Section 3.01(b) and a written notice to Eiken. Effective upon such exercise of the option, the license set forth in Section 2.01 shall automatically be
amended and expanded to be worldwide (the Licensed Territory). 

  
 4 

 Section 2.03.
Subject to the terms and conditions set forth herein, Eiken hereby grants to Lucira, and Lucira hereby accepts, during the effective term hereof, an option for non-transferable,
non-assignable (except in connection with a permitted assignment pursuant to Section 9.01), non-exclusive license, with the right to sublicense in accordance with
Section 2.05, under the LAMP Patents to develop and make the Licensed Products for each new additional target designated in writing by Lucira (the “Additional Target”) in the Field in the United States of America, and use, sell, offer
for sale or otherwise dispose of such Licensed Products so made under Lucira’s own labels in the Field in the United States of America. Lucira may exercise the option for each Additional Target at any time upon the payment of the fee set forth
in Section 3.01(c) and a written notice to Eiken, which notice shall contain the name of each Additional Target. Effective upon such exercise of the option with respect to each Additional Target, the foregoing license shall automatically go
into effect. 
 Section 2.04. Subject to the terms and conditions set forth herein, Eiken hereby grants to
Lucira, and Lucira hereby accepts, during the effective term hereof, an option to expand the licensed territory from the United States of America to anywhere in the world under the license set forth in Section 2.03. Lucira may exercise the
option at any time upon the payment of the fee set forth in Section 3.01(d) and a written notice to Eiken. Effective upon such exercise of the option, the license set forth in Section 2.03 shall automatically be amended and expanded to be
worldwide. 
 Section 2.05. Subject to compliance with the terms
and conditions hereof, Lucira shall have the right to grant to its Affiliates sublicenses under the license and rights granted to it hereunder but without any right to sublicense further. Lucira shall give Eiken written notice as to the names,
addresses, shareholding ratio, and any other information reasonably requested by Eiken from time to time with respect to all the Affiliates sublicensed hereunder that manufacture the Licensed Products. Each such Affiliate shall be bound by the terms
and conditions hereof as if it were named herein in the place of Lucira. The sublicense granted hereunder to an Affiliate shall automatically terminate on the date the Affiliate ceases to be an Affiliate. Lucira shall not have the right to grant a
sublicense to any person other than its Affiliates. 

Section 2.06. The license to “make” the Licensed Products
granted in Sections 2.01 and 2.03 include the right under the LAMP Patents to have a third party manufacturer designated by Lucira or its Affiliates sublicensed hereunder and approved in advance by Eiken in writing, such approval not to be
unreasonably withheld (except for the third party manufacturers set forth in Schedule IV which are hereby approved), make the Licensed Products and any component thereof either in finished or semi-finished form in accordance with the designs,
drawings and specifications and manufacturing and/or assembling drawings or specifications, all originated and owned by Lucira or such Affiliates, provided that Lucira or such Affiliates shall purchase and take over from such third party
manufacturer all of the Licensed Products manufactured and/or all portions thereof assembled by the third party manufacturer and shall not directly or indirectly re-transfer them to such third party
manufacturer or any related parties of such third party manufacturer. For the avoidance of doubt, a drop shipment of the Licensed Products by such third party manufacturer to Lucira’s or its Affiliates’ customers shall not be considered to
be in violation of this Section 2.06. 

  
 5 

 Section 2.07. Except for the licenses, options and rights
expressly granted hereunder, no right, title or interest in any discovery, invention or technology, data or information or any patent, copyright, trademark or other intellectual property right owned by Eiken or its Affiliate shall be granted to
Lucira hereunder, by implication or otherwise. Eiken shall not be under any obligation to grant to Lucira any additional licenses and rights other than those granted hereby. 

ARTICLE III 

LICENSE FEES AND ROYALTIES 

Section 3.01. In consideration of the licenses and rights granted herein, Lucira shall pay to Eiken a non-refundable license fees (the “License Fees”) as follows: 
  

	 	(a)	 with respect to the Initial Target for the license in the United States of America under Section 2.01:

  

	 	(i)	 [****], which shall be due and payable within [****] after the Effective Date; and 

 

	 	(ii)	 [****], which shall be due and payable within [****] after the Effective Date. 

 

	 	(b)	 with respect to the Initial Target for the world-wide license under
Section 2.02: 

  

	 	(i)	 [****], which shall be due and payable upon exercise of the option pursuant to Section 2.02; and

  

	 	(ii)	 [****], which shall be due and payable within [****] after exercise of the option pursuant to
Section 2.02. 

  

	 	(c)	 with respect to each Additional Target for the license in the United States of America under Section 2.03:

  

	 	(i)	 [****], which shall be due and payable upon exercise of the option for each Additional Target pursuant to
Section 2.03. 

  

	 	(d)	 with respect to each Additional Target for the world-wide license under Section 2.04:

  

	 	(i)	 [****], which shall be due and payable upon exercise of the option for each Additional Target pursuant to
Section 2.04. 

 Section 3.02. In
consideration of the licenses and rights granted herein, Lucira shall further pay to Eiken non-refundable running royalties (the “Running Royalties”) of [****] percent ([****]%) of the
total Net Sales of all the Licensed Products made, used, sold or otherwise disposed of by Lucira or any of its Affiliates in the Field in the Licensed Territory. 

Section 3.03. Running Royalties shall accrue at the time when any
Licensed Product is first sold, used or otherwise disposed of, as evidenced by the applicable invoice or bill, whether or not payment is received by Lucira or its Affiliates hereunder. No Running Royalties shall accrue at the time of the transfer,
sale or disposal of the Licensed Products by Lucira to any of its Affiliates or any of its Affiliates to another Affiliate. In such event, Running Royalties shall accrue at the time of the use, sale or disposal of the Licensed Products by such other
Affiliates to Arm’s Length Customers in the Field in the Licensed Territory. 
 Section 3.04. For the
avoidance of doubt, any portion of the License Fees paid to Eiken shall not be credited against any Running Royalties due and payable to Eiken hereunder. 

  
 6 

 ARTICLE IV 

PAYMENT AND ROYALTY REPORTS 

Section 4.01. Running Royalties accrued during each quarter (any part in the first or last quarter) during the
term of this Agreement shall be paid to Eiken or any other person designated by Eiken in writing from time to time within [****] ([****]) days after the end of such quarter. 

Section 4.02. Each Running Royalty payment shall be accompanied by a royalty report, substantially in the form
attached hereto as Schedule II covering the immediately preceding quarter showing the computation of Running Royalties for such quarter. Each royalty report shall set out by product name, model and type of each of the Licensed Products used, sold or
otherwise disposed of during the relevant quarter, the name of the manufacturer (whether Lucira or any of its Affiliates or third party manufacturers hereunder), the unit price, the quantities, the gross amount received, the relevant currency, the
deductible items set forth in the definition of the Net Sales and the total Net Sales of the Licensed Products. The royalty report shall also contain a calculation of the Running Royalties in [****] due under this Agreement and the exchange rates
used therefor. The royalty report shall be certified by an authorized officer of Lucira to be correct to the best knowledge and information of Lucira. If no Running Royalties have accrued during a quarter, the royalty report shall so state. 

Section 4.03. The License Fees, Running Royalties and any other amount payable to Eiken hereunder shall be
payable to Eiken in [****] without any deduction of any remitting bank commission or fee or otherwise at the following bank account of Eiken or any other bank account Eiken notifies Lucira in writing from time to time: 

Bank Name: [****] 
 Branch Name:
[****] 
 Bank Address: [****] 

Type of Bank Account: [****] 

SWIFT Code: [****] 
 Bank Account
Number: [****] 
 Name of the Bank Account holder: [****] 

Section 4.04. For sales of Licensed Products made in currencies other
than [****] during a quarter, Running Royalties shall be computed by converting the Net Sales into [****] at the wire transfer selling rate of exchange in effect on the closing of the last banking day during such quarter as quoted by [****]. 

Section 4.05. The Parties agree that the payments due to Eiken
hereunder constitute “royalties” as that term is defined in Article 12, paragraph 2 of the Convention between Japan and the United States of America for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with respect to
Taxes on Income and on Capital Gains (the “Treaty”) and, as such, are exempt from US withholding tax under Article 12, paragraph 1 of the Treaty. Pursuant to such exemption, Lucira shall not withhold any tax from any payments due to Eiken
hereunder, and Eiken shall not be liable for any withholding taxes involved in this transaction. Eiken shall, in addition to providing a certificate of Japanese residency, complete all forms required for Lucira to obtain such exemption and provide
Lucira with such forms. Upon Lucira’s request, Eiken shall submit a certificate of the Japanese residency, and an executed form W-8BEN-E to Lucira. 

  
 7 

 Section 4.06.
Within [****] ([****]) days after expiration or termination of this Agreement, Lucira shall furnish to Eiken a royalty report as set forth in Section 4.02 covering the Net Sales of the Licensed Products used, sold or otherwise disposed of prior
to the expiration or termination date but as to which no Running Royalties were previously paid, which report also shall set forth the total quantity of Lucira’s, its Affiliates’ and third party manufacturers’ inventory (including work-in-process) of the Licensed Products existing as of the expiration or termination date and in possession of Lucira, all of its Affiliates and third party manufacturers,
and Lucira shall simultaneously pay Running Royalties to Eiken with respect to the Licensed Products made, used or sold and inventory thereof. The Running Royalties with respect to Lucira’s, its Affiliates’ and third party
manufacturers’ inventory existing as of the expiration or termination date shall be determined as if such inventory were sold immediately prior to the expiration or termination date. 

Section 4.07. In the event that any amount due Eiken by Lucira hereunder is not paid when due, Lucira shall pay
on demand to Eiken interest on the overdue amount at the Interest Rate from the due date of such amount until the date such overdue amount is paid in full. 

Section 4.08. Lucira shall keep, and Lucira shall cause its
Affiliates to keep, accurate and complete records and books of account containing regular entries in accordance with the USGAAP consistently applied for the purpose of calculating Running Royalties and making royalty reports pursuant to
Section 4.02. All the records and books of account relating to a particular fiscal year of Lucira and such Affiliates shall be retained for a period of [****] ([****]) years following the close of such fiscal year. All records and books of
account shall contain all information necessary to calculate Running Royalties due hereunder and to determine the accuracy of the royalty reports. Eiken shall have the right (which it may not exercise more than once for each year) to cause such
records and books of account to be audited by an independent public accounting firm selected by Eiken which does not have conflicts for the sole purpose of determining the accuracy of reports and calculations of Running Royalties. Such audits shall
be made during normal business hours of Lucira or such Affiliates and with at least [****] ([****]) day prior written notice. Such audits shall not be conducted for any calendar year more than [****] years after the end of such year, or repeated for
any calendar year or with respect to the same set of records. All information disclosed to or obtained by the independent public accounting firm during such audit shall not be disclosed to anyone including Eiken (except as required by law or by any
governmental authority, and except as may be necessary in connection with any dispute resolution proceeding relating to this Agreement) and shall be held in strictest confidence, except that the independent public accounting firm may disclose to
Eiken whether a discrepancy in Running Royalty payments has been found and the amount of the discrepancy involved, and the circumstance of the discrepancy, including the basis upon which the discrepancy is determined. In the event that such audit
reveals that Lucira underpaid or under-reported Running Royalties due Eiken hereunder, Lucira shall promptly upon demand pay to Eiken the deficiency and interest thereon under Section 4.07, and if such deficiency is in excess of [****] percent
([****]%) of the amount actually due, Lucira shall also upon demand from Eiken reimburse Eiken for the costs and expenses actually incurred in conducting such audit on an indemnity basis. 

  
 8 

 Section 4.09.
Lucira shall faithfully respond with reasonable additional information to what Eiken may reasonably request from time to time to enable Eiken to ascertain a specific model or type of Licensed Products used, sold or otherwise disposed of by Lucira or
its Affiliates that is subject to the payment of Running Royalties pursuant to Section 4.01, and the amount of such Running Royalties due. 

ARTICLE V 

PATENT MARKING 
 Lucira shall mark,
and shall cause its Affiliates sublicensed hereunder to mark (i) each of the Licensed Products made, used, offered for sale or sold, (ii) its containers, and the product brochures and promotional and sales materials for the Licensed
Products, or (iii) each such Licensed Products in the form of “virtual marking” on a free-to-access web page, with the patent numbers of the LAMP Patents
utilized therefor, and shall furnish to Eiken samples of each of the Licensed Products or their containers and each copy of those product brochures and materials. 

ARTICLE VI 

GRANT BACK 
 Lucira hereby grants,
and causes its Affiliates to grant, to Eiken and its Affiliates, [****] right and license under Lucira Improvements (as defined below) to [****]. Such license includes the right for Eiken and its Affiliates to use any Lucira Improvements as part of
[****]. Promptly after Lucira becomes aware of any Lucira Improvements, Lucira shall inform Eiken thereof in writing in such reasonable manner and details as Eiken will be able to review, make further inquiries and utilize the same. For purpose of
this Agreement, “Lucira Improvements” means any discovery, invention or improvement made by or for Lucira and/or its Affiliates in the course of developing, manufacturing, using or testing the Licensed Products and any patent therefrom
owned by Lucira and/or its Affiliates, to the extent that [****]. For the avoidance of doubt, any such Lucira Improvement which [****] shall not be required to be licensed to Eiken and its Affiliates under this grant back clause, [****]. Nothing
contained herein shall be in any way construed to mean that Lucira hereby grants to Eiken licenses under the Lucira Technology which Lucira warrants and represents do not constitute any Lucira Improvements. 

ARTICLE VII 

NO WARRANTIES 

Section 7.01. Nothing in this Agreement shall be construed as: 

 

	 	(a)	 a warranty, representation or promise by Eiken relating to any of the LAMP Patents or the Licensed Products,
including the validity, scope or suitability for any purpose of the LAMP Patents; or 

  

	 	(b)	 an obligation on the part of Eiken to furnish any manufacturing or technical information to Lucira or its
Affiliates; or 

  

	 	(c)	 an obligation to bring or prosecute actions or suits against third parties, defend actions or suits brought
against Lucira, its Affiliates, their customers or third parties, or indemnify Lucira, its Affiliates, their customers or third parties for any reason; or 

  
 9 

	 	(d)	 imposing any liability on Eiken with respect to the manufacture, use, sale or disposal of the Licensed Products
by Lucira, its Affiliates, their customers or third parties; or 

  

	 	(e)	 imposing an obligation on Eiken to maintain the continued existence of any of the LAMP Patents or to file
applications for any patent or other industrial or intellectual property right or to take any action with respect to filed applications for any patent or other industrial or intellectual property rights; or 

 

	 	(f)	 conferring upon Lucira or its Affiliates the right to use in advertising, publicity or otherwise, any
trademark, service mark or trade name of Eiken, except in the case of Article V; or 

  

	 	(g)	 an obligation upon Eiken to make any determination as to the applicability of any of the LAMP Patents to any
products of Lucira or its Affiliates. 

 Section 7.02. [****]. 

Section 7.03. [****] EIKEN MAKES NO WARRANTIES, REPRESENTATIONS OR PROMISES THAT THE USE OR PRACTICE OF THE
LAMP PATENTS OR THE DEVELOPMENT, MANUFACTURE, USE, OFFER FOR SALE OR SALE OF THE LICENSED PRODUCTS DOES NOT AND WILL NOT INFRINGE ANY PATENT OR OTHER INDUSTRIAL OR INTELLECTUAL PROPERTY RIGHT OR OTHER RIGHT OWNED BY THIRD PARTIES. THE LICENSES AND
RIGHTS PROVIDED FOR HEREIN ARE GRANTED WITHOUT WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

ARTICLE VIII 

TERM AND TERMINATION 

Section 8.01. This Agreement shall become effective on the Effective Date. 

Section 8.02. Except as otherwise provided for in this Article VIII, this Agreement, the licenses
and rights granted pursuant hereto shall remain in effect until the last to expire of the LAMP Patents. 

Section 8.03. Lucira shall have the right to terminate this Agreement at any time for any reason, upon giving
[****] days’ written notice to Eiken after Eiken has received the payments set forth in Section 3.01(a) and all the Running Royalties accrued up to the termination date, together with the royalty reports for the Running Royalties set forth
in Section 4.02. 
 Section 8.04. Eiken shall have the right forthwith to terminate this
Agreement upon written notice to Lucira in any of the following events: 
  

	 	(a)	 if Eiken has not received any Running Royalties on the Licensed Products for [****] ([****]) year after Lucira
commences the sales of the Licensed Products; 

  

	 	(b)	 if Lucira or any of its Affiliates sublicensed hereunder has defaulted in the performance or observance of any
provision, covenant, condition or agreement contained in this Agreement and has failed to cure such default within [****] ([****]) days of written notice to Lucira describing such default; 

  
 10 

	 	(c)	 if Lucira becomes insolvent or admits in writing its inability to pay its debts as the same become due or makes
an assignment for the benefit of creditors; 

  

	 	(d)	 if any proceeding is instituted by or against Lucira seeking to adjudicate it bankrupt or insolvent, or seeking
dissolution, liquidation, winding up, reorganization, arrangement, adjustment, protection, relief or composition of Lucira or its debts or seeking the entry of an order for relief or the appointment of a receiver, trustee, custodian or other similar
official for Lucira or for any substantial part of its property and assets; and 

  

	 	(e)	 if Lucira assigns or attempts to assign this Agreement or any part thereof in violation of Section 9.01.

 Section 8.05. In the event that Lucira or any of its Affiliates for itself
or through any third party files any declaratory judgment or similar action contesting the validity of any of the LAMP Patents or assists any third party in filing any such action contesting the validity of any of the LAMP Patents, to the extent
permissible by applicable law, Eiken shall have the right forthwith to terminate this Agreement or the specific licenses and rights granted hereunder in respect of such LAMP Patent upon written notice to Lucira, and the corresponding sublicenses
shall likewise terminate without any notice to its Affiliates. 
 Section 8.06. In the event that Lucira
becomes subject to a Change of Control, and unless Lucira delivers to Eiken, in writing within [****] ([****] ) days of the Change of Control, a legally binding undertaking from the third person thereafter in control of Lucira (including the entity,
if any, that ultimately controls such third person) (on behalf of itself and entities that would constitute Affiliates) to be bound by the terms and conditions of this Agreement to the same extent as if such third person (or such controlling entity)
were the party to this Agreement subject to the consent of Eiken, then Eiken shall have the right to terminate this Agreement upon written notice to Lucira, and the corresponding sublicenses shall likewise terminate without any notice to its
Affiliates. 
 Section 8.07. All licenses and rights granted to Lucira hereunder in respect of
the LAMP Patents shall cease forthwith as of the date of expiration or termination of this Agreement. In the event that this Agreement is terminated for whatever reason or expired, all the corresponding sublicenses granted to the Affiliates of
Lucira shall likewise terminate without any notice to such Affiliates. 
 Section 8.08. Any expiration
or termination of this Agreement pursuant to this Article VIII shall not relieve Lucira of any of its obligations or liabilities accrued hereunder prior to the date of expiration or termination of this Agreement, and the expiration or
termination shall not affect in any manner any rights of Eiken arising under this Agreement prior thereto. 

Section 8.09. The rights and remedies set forth in this Article VIII are not exclusive and are in
addition to any other rights and remedies available to Eiken under this Agreement or at law or in equity. 

Section 8.10. For the convenience of the Parties, this Agreement is made for patent licenses under a certain
group of patents owned by Eiken. Any judgment, adjudication, determination or order by a competent court or a regulatory authority or governmental agency which finds one or more of the LAMP Patents invalid or unenforceable shall not give rise to a
right of termination hereof or reduction of the License Fees or Running Royalties by Lucira, as long as one or more of the LAMP Patents remain valid. 

  
 11 

 Section 8.11. The provisions of Articles I, III, VI and VII
and Sections 4.02 through 4.09, 8.08, 8.09, 9.03, 9.08, 9.10, 9.11, 9.13 and 9.15 and this Section 8.11 shall survive the expiration or termination of this Agreement. 

ARTICLE IX 

MISCELLANEOUS 

Section 9.01. This Agreement and the licenses and rights granted herein shall be binding upon and inure to the
benefit of Eiken, Lucira and their respective permitted successors and assigns. Except for consummation of its initial public offering, Lucira shall not assign or transfer any of its rights, privileges or obligations hereunder without prior written
consent of Eiken. For the purpose of this Agreement, [****] any consolidation or merger by any third party with Lucira where the third party is the surviving entity or any sale of all or substantially all of the assets of Lucira relating to the
business contemplated by this Agreement to any third party shall be construed to be an assignment hereunder. [****] Any assignment or transfer in violation of this Section 9.01 shall be null and void ab initio. 

Section 9.02. This Agreement does not in any way create a relationship of principal and agent, partnership or
joint venture between the Parties. Neither Party shall under any circumstances act as, or represent itself to be, the other Party. 

Section 9.03. Any notice, report or other document required or
permitted hereunder shall be written in English, and shall be sufficiently given when personally delivered, delivered by overnight courier or mailed prepaid first class registered or certified mail and addressed to the Party for whom it is intended
at its record address set forth below, and such notice shall be effective upon receipt, if delivered personally or delivered by overnight courier, or shall be effective [****] ([****] ) days after it is deposited in the mail, if mailed. The record
addresses of the Parties are set forth below: 
  

			
	Eiken:	  	[****]
	Lucira:	  	[****]

 Either Party, at any time, may change its previous record address by giving written notice of the substitution in accordance
with the provision of this Section 9.03. 
 Section 9.04.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement or portion thereof, or the application thereof to any person or
circumstance or in any country contravenes a law of any country (or political subdivision thereof) in which this Agreement is effective or is held to any extent invalid or unenforceable by a court of competent jurisdiction, the remaining provisions
of this Agreement (or of such provision) and the application thereof to other persons or circumstances or in other countries shall not be affected thereby, and this Agreement shall be modified with respect to its application in such jurisdiction,
but not in jurisdictions where such provision is valid, to conform with such law. 

  
 12 

 Section 9.05. No modification or amendment hereof shall be
valid or binding upon the Parties, unless made in writing and duly executed on behalf of the Parties by their respective duly authorized officers. 

Section 9.06. Any failure of either Party to insist upon the strict performance of any provision hereof or to
exercise any right or remedy shall not be deemed a waiver of any right or remedy with respect to any existing or subsequent breach or default. 

Section 9.07. This Agreement constitutes the entire understanding and agreement of the Parties with respect to
the subject matter hereof and supersedes all prior agreements, express or implied, and oral or written. 

Section 9.08. This Agreement shall be governed by, and shall be
construed, and the legal relations between the Parties shall be determined, in accordance with the laws of Japan without regard to what laws might otherwise govern under applicable principles of conflict or choice of laws. 

Section 9.09. This Agreement may be executed in any number of counterparts, each of which shall be deemed an
original, but all of which together shall constitute a single instrument. 
 Section 9.10. Any
dispute, controversy or difference arising out of, in relation to or in connection with, this Agreement shall be settled in good faith between the Parties. If the Parties fail to resolve such dispute, controversy or difference through the good faith
negotiations, it shall be finally settled by arbitration in Tokyo, Japan in accordance with the Rules of Arbitration of the International Chamber of Commerce for the time being in force by a panel of three (3) arbitrators. The language of the
arbitration shall be English. The prevailing Party shall be entitled to receive from the losing Party reimbursement for all costs incurred in such arbitration proceedings, including reasonable attorneys’ fees. The decision and award of the
arbitration shall be final and binding, and shall be enforceable in any court of competent jurisdiction. 

Section 9.11. The Parties shall maintain the confidentiality of the terms of this Agreement, and shall not
disclose or transfer, without the prior written consent of the other Party, such terms or any part thereof to any third party, except 
 (a)
as otherwise may be required by law, order or regulation; or 
 (b) to any competent court, regulatory authority or governmental agency
which has ordered the same to be produced; provided, however, that the Party who has been so ordered shall promptly notify the other Party of such order and use its best efforts to preserve the confidentiality thereof to the extent possible
in compliance with such order including obtaining a protective order. 
 Section 9.12. Neither
Party shall issue any press release or other public announcement relating to this Agreement without obtaining the other Party’s written approval. 

Section 9.13. The Parties hereby acknowledge that there are circumstances in which
it would be impossible to measure in money the injury that would be suffered by Eiken or Lucira, as relevant, by reason of the other Party’s breach of its obligations hereunder, and in the event that such circumstances apply, the breaching
Party consents to the granting by any court in 

  
 13 

 
any applicable jurisdiction of an injunction or other equitable relief. The foregoing shall be in addition to all other rights and remedies available to the
non-breaching Party under this Agreement or at law or in equity. 

Section 9.14. Lucira shall fully comply with all laws, ordinances and regulations applicable to it with respect
to the development, manufacture, use or sale of the Licensed Products hereunder or any other performance to be made by Lucira hereunder. 

Section 9.15. Lucira hereby agrees to defend, indemnify and hold
harmless Eiken, its Affiliates, and their respective directors, officers employees and agents from and against any and all third-party claims, actions, suits, liabilities, damages or judgments resulting from or relating to the activities of Lucira
and its Affiliates sublicensed hereunder or the manufacture, use, sale or other disposal of the Licensed Products by Lucira, its Affiliates or any other person (including third-party claims, actions, suits, liabilities, damages or judgments related
to product liability). Lucira shall assume responsibility for all costs and expenses related to any such third-party claims, actions, suits, liabilities, damages or judgments including reasonable attorneys’ fees and other litigation costs and
expenses. 
 Section 9.16. Each Party hereby represents and warrants to the other party that it has the right
and power to execute, deliver and perform this Agreement, and that its performance hereof will not result in a breach of or constitute a default under its articles of incorporation or bylaws, if any, or any contract between it and a third party.

 IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by its duly authorized officer as of the date and year
first above written. 
  

									
	EIKEN CHEMICAL CO., LTD.	  		  	LUCIRA HEALTH, INC.
	  
	  	            	  	  

	By:	  	[****]	  		  	By:	  	[****]
	Title:	  	[****]	  		  	Title:	  	[****]
	Date:	  		  		  	Date:	  	

  
 14 

 Schedule I 

LAMP Patents 
 [****]

  
 15 

 Schedule II 

Form of Royalty Report 

[***] 

  
 16 

 Schedule III 

Lucira Technology 

[****] 

  
 17 

 Schedule IV 

Pre-Approved third party manufacturers 

 

	 	•	 	 [****] 

  

	 	•	 	 [****] 

  

	 	•	 	 [****] 

  
 18EX-10.14

 Exhibit 10.14 

LUCIRA HEALTH, INC. 

January 13, 2021 
 Erik T. Engelson 

Lucira Health, Inc. 
 1412 62nd Street 
 Emeryville, CA 94608 
  

	Re:	 Amended and Restated Employment Agreement 

Dear Erik: 
 You are currently employed by
LUCIRA HEALTH, INC. (the “Company”) under the terms of an offer letter between you and the Company dated February 5, 2019 (the “Offer Letter”). The
Company is amending and restating the terms of the Offer Letter to reflect your new employment terms as set forth in this employment agreement (the “Agreement”). Once you accept this Agreement by signing and returning it to
the Company, this Agreement shall supersede and replace your Offer Letter in its entirety, and this Agreement shall then govern the terms of your employment with the Company. 

1. EMPLOYMENT BY THE COMPANY. 

(a) Position. You will continue to serve as the Company’s President and Chief Executive Officer. 

(b) Duties and Location. You will perform those duties and responsibilities as are customary for the position of President and Chief
Executive Officer and as may be directed by the Board of Directors of the Company, to whom you will report. Your primary office location will be the Company’s offices in Emeryville, California. Notwithstanding the foregoing, the Company
reserves the right to reasonably require you to perform your duties at places other than your primary office location from time to time, and to require reasonable business travel. Subject to the terms of this Agreement, the Company may modify your
job title, duties, and reporting relationship as it deems necessary and appropriate in light of the Company’s needs and interests from time to time. 

(c) Outside Activities. Throughout your employment with the Company, you may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of your duties hereunder or present a conflict of interest with the Company. During your employment by the Company,
except on behalf of the Company, you will not directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venturer, associate, representative or consultant of any other person, corporation, firm,
partnership or other entity whatsoever known by you to compete with the Company (or is planning or preparing to compete with the Company), anywhere in the world, in any line of business engaged in (or planned to be engaged in) by the Company;
provided, however, that you may purchase or otherwise acquire up to (but not more than) one percent (1%) of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on
any national or regional securities exchange. 
 2. COMPENSATION AND BENEFITS. 

(a) Base Salary. You will continue to be paid a base salary at the rate of $400,000 per year. Effective commencing on the date of the
underwriting agreement between the Company and the underwriters managing the initial public offering of the Company’s common stock (the “IPO”), pursuant to which such stock is priced for the initial public offering (the “IPO
Date”), your base salary will be automatically increased to $525,000 per year. In all cases, your base salary will be paid on the Company’s ordinary payroll cycle, less applicable payroll deductions and withholdings. As an exempt salaried
employee, you will be required to work the Company’s normal business hours, and such additional time as appropriate for your work assignments and position, and you will not be entitled to overtime compensation. 

  
 1 

 (b) Employee Benefits. As a regular full-time employee, you will be eligible to
participate in the Company’s standard employee benefits offered to executive level employees, as in effect from time to time and subject to the terms and conditions of the benefit plans and applicable Company policies. A full description of
these benefits is available upon request. Subject to the terms of this Agreement, the Company may change your compensation and benefits from time to time in its discretion. 

(c) Annual Discretionary Bonus. You will also be eligible to earn an annual discretionary bonus with a target amount equal to 83% of
your annual base salary. The amount of this bonus will be determined in the sole discretion of the Company and based, in part, on your performance and the performance of the Company during the calendar year, as well as any other criteria the Company
deems relevant, as set forth in the Company’s Employee Bonus Program or any successor bonus program sponsored by the Company. 
 (d)
Equity Compensation. 
 (i) Outstanding Equity Awards. Any and all Company stock options, restricted stock, restricted stock
units or other Company equity awards previously granted to you will continue to be governed by the terms of the applicable equity plan, forms of award agreements and grant notices for such equity awards. For purposes of this Agreement, “equity
awards” shall mean all stock options, restricted stock, restricted stock units, and any other Company equity awards. 
 (ii)
IPO Option Grant. In the event that the Company completes an IPO, on the IPO Date you will be granted an option to purchase shares of the Company’s Common Stock (the “Option”). The Option will have an exercise price equal
to the per share price that the Company’s Common Stock is sold on the IPO Date in its initial public offering. The Option will be for a number of shares of the Company’s Common Stock so that the Option will have a grant date fair value for
financial accounting purposes equal to $2,783,000. The Option will be granted pursuant to and subject to the terms of the Company’s 2021 Equity Incentive Plan, which will automatically become effective on the IPO Date, and its standard form of
Option Grant Notice and Stock Option Agreement. The Option will vest subject to your continued services with the Company over a four-year period, whereby twenty-five percent (25%) of your Option shares will vest on the one year anniversary of the
IPO Date, with the remaining shares subject to the Option vesting in thirty-six (36) equal monthly installments thereafter, in each case subject to your continued services with the Company through the
applicable vesting dates. 
 (e) Officer Severance Benefit Plan. You will be eligible to participate in the Company’s Officer
Severance Benefit Plan (the “Severance Plan”) subject to the terms and conditions of the Severance Plan. A copy of the Severance Plan has been provided to you concurrently with this Agreement. 

(f) Expenses. The Company will reimburse you for reasonable travel, entertainment or other expenses incurred by you in furtherance of or
in connection with the performance of your duties hereunder, in accordance with the Company’s expense reimbursement policies and practices as in effect from time to time. 

3. CONFIDENTIAL INFORMATION. 

(a) Confidentiality Agreement. As a Company employee, you will be expected to continue to abide by Company rules and policies including
those rules and policies regarding the protection of the Company’s confidential information. You will remain subject to the terms of the attached Employee Confidential Information and Inventions Assignment Agreement that you signed when you
joined the Company, which prohibits unauthorized use or disclosure of the Company’s proprietary information, among other obligations (the “Confidentiality Agreement”), and which is incorporated herein by reference. 

  
 2 

 (b) Conflicting Obligations. By signing this Agreement, you are representing that you
have full authority to accept this position and perform the duties of the position without conflict with any other obligations and that you are not involved in any situation that might create, or appear to create, a conflict of interest with respect
to your loyalty or duties to the Company. You specifically warrant that you are not subject to an employment agreement or restrictive covenant preventing full performance of your duties to the Company. You agree not to bring to the Company or use in
the performance of your responsibilities at the Company any information, materials or documents of a former employer that are not generally available to the public, unless you have obtained express written authorization from the former employer for
their possession and use. You also agree to honor all obligations to former employers during your employment with the Company. 
 4.
AT-WILL EMPLOYMENT RELATIONSHIP. Your employment relationship with the Company is at will. Accordingly, you may terminate your employment
with the Company at any time and for any reason whatsoever simply by notifying the Company; and the Company may terminate your employment at any time, with or without Cause or advance notice. If your employment is terminated by you or the Company
for any reason, you agree to resign from any position you hold on the Company’s Board of Directors (“Board”), to be effective no later than the date of your termination (or such other date as requested by the Board).

 5. COMPLIANCE WITH OR EXEMPTION FROM
SECTION 409A. It is intended that the benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A of the Internal
Revenue Code of 1986, as amended, (the “Code”) (Section 409A, together with any state law of similar effect, “Section 409A”) provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). With respect to reimbursements or in-kind
benefits provided to you hereunder (or otherwise) that are not exempt from Section 409A, the following rules shall apply: (i) the amount of expenses eligible for reimbursement, or in-kind benefits
provided, during any one of your taxable years shall not affect the expenses eligible for reimbursement, or in-kind benefit to be provided in any other taxable year, (ii) in the case of any reimbursements
of eligible expenses, reimbursement shall be made on or before the last day of your taxable year following the taxable year in which the expense was incurred, (iii) the right to reimbursement or in-kind
benefits shall not be subject to liquidation or exchange for another benefit. 
 6. DISPUTE RESOLUTION. 

(a) Arbitration Agreement. To ensure the rapid and economical resolution of disputes that may arise in connection with your employment
with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation
of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. § 1-16, to the fullest extent permitted by
law, by final, binding and confidential arbitration conducted by JAMS, Inc. or its successor (“JAMS”), under JAMS’ then applicable rules and procedures for employment disputes before a single arbitrator (available upon
request and also currently available at http://www.jamsadr.com/rules-employment-arbitration/). You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a
trial by jury or judge or administrative proceeding. 
 (b) Individual Claims. All claims, disputes, or causes of action under
this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the
claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding
class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to
any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and
Housing Act, as amended, and the California Labor 

  
 3 

 
Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law(s) are not preempted by the Federal Arbitration
Act or otherwise invalid (collectively, the “Excluded Claims”). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be publicly filed with a court,
while any other claims will remain subject to mandatory arbitration. 
 (c) Process. You will have the right to be represented by
legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this agreement shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final
disposition are also matters for the arbitrator. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a
written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based.
The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the
dispute were decided in a court of law. 
 (d) Injunctive Relief. Nothing in this letter agreement is intended to prevent either you
or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts
of any competent jurisdiction. 
 7. MISCELLANEOUS. This Agreement, together with your Confidentiality Agreement, forms the
complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises made to you by anyone, whether oral or written, including but not limited to the Offer Letter. Changes in your employment
terms, other than those changes expressly reserved to the Company’s or the Board’s discretion in this Agreement, require a written modification approved by the Company and signed by a duly authorized officer of the Company (other than
you). This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is
determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with
the intent of the parties insofar as possible under applicable law. This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. Any ambiguity in this Agreement
shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. This Agreement may be
delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall
be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes. 
 SIGNATURE
PAGE FOLLOWS 

  
 4 

 Please sign and date this Agreement and return a signed copy to me on or before
January 14, 2021 to confirm your acceptance of this Agreement. 
  

							
	LUCIRA HEALTH, INC.	 		  		  	
				
	 /s/ David Lamond
	 		  		  	
	David Lamond	 		  		  	
	Chairman of the Board of Directors	 	            	  		  	
				
	Accepted and Agreed:	 		  		  	
				
	 /s/ Erik T. Engelson
	 		  	 January 14, 2021
	  	
	Erik T. Engelson	 		  	Date	  	

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]